Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)

The global prescription drugs market is on the cusp of a significant expansion, with recent market reviews and forecasts projecting a robust growth trajectory through 2035. This anticipated surge, driven by an aging global population, the rising prevalence of chronic diseases, and relentless innovation in pharmaceutical research and development, signals

Stanley Druckenmiller is considered one of the greatest investors of all time.

Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.

JPMorgan said the implied net impact aligns with recent commentary from Novo Nordisk, Teva and AbbVie during earnings season.

Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA.

Jury convicts Done Global founder Ruthia He and former top doctor David Brody in a federal case alleging illegal Adderall distribution through the telehealth platform.

Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation.

Duquesne Family Office's billionaire boss has gone full contrarian by selling Wall Street's two artificial intelligence (AI) darlings and piling into a previously struggling pharmaceutical stock.

Expedia, SanDisk, and Penumbra led last week's large-cap gainers, with strong earnings and raised guidance fueling broad double-digit jumps.

The company delivered a convincing pair of beats in its third-quarter earnings report.

Teva Q3 revenue rose to $4.48 billion, beating estimates, as Austedo and Ajovy boosted growth; 2025 EPS outlook now $2.55–$2.65.

In a period marked by cautious optimism and strategic pivots, several prominent companies across diverse sectors have recently defied broader economic uncertainties to achieve significant 52-week highs. As of late 2025, pharmaceutical giant Eli Lilly, defense and safety solutions provider Cadre Holdings, energy major BP, global food company Kellanova, and

Teva stock jumped Wednesday on better-than-expected quarterly metrics.

Here's Why This Israeli Investment Giant Is Betting $834 Million on Teva Stock

Israel’s Phoenix Financial Exits $169 Million Tower Semiconductor Stake After Stock's 99% Rally

Harel Bets Big on Teva Pharmaceutical by Purchasing 4.3 Million Shares

SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures.

Druckenmiller is considered one of the best investors of all time.

The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns.